Yahoo
NYSE - Delayed Quote USD

Quest Diagnostics Incorporated (DGX)

259.67 +4.04 (+1.58%)
At close: November 9 at 4:00:02 PM EST
259.67 0.00 (0.00%)
After hours: November 9 at 4:00:40 PM EST
Trade DGX on Coinbase
Chart Range Bar
Loading chart for DGX
Chart does not reflect overnight price.

What's happening with DGX?

49m ago
Powered by Yahoo Scout

Quest Diagnostics has scheduled two investor conference appearances for November 17 and December 1, 2026. Its latest reported quarter showed strong revenue and earnings growth, while a potential 1% of 2027 revenue reimbursement headwindand a recently disclosed cybersecurity incident remain key issues. DGX rose 1.58% on November 9on a full-day basis, including regular-session and after-hours trading.

Powered by Yahoo Scout
  • Previous Close 255.63
  • Open 257.34
  • Bid --
  • Ask --
  • Day's Range 255.08 - 259.84
  • 52 Week Range 171.18 - 259.84
  • Volume 1,041,776
  • Avg. Volume 1,012,345
  • Market Cap (intraday) 28.661B
  • Beta (5Y Monthly) 0.55
  • PE Ratio (TTM) 25.86
  • EPS (TTM) 10.04
  • Earnings Date Oct 22, 2026
  • Forward Dividend & Yield 3.44 (1.35%)
  • 1y Target Est 257.27
  • Morningstar Rating Rating available with Stock Picks access

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. In addition, the company offers risk assessment services for the life insurance industry; healthcare IT healthcare providers and payers; testing and medical director services at hospital laboratories; test offerings in cardiometabolic and endocrine; cancer; clinical drug monitoring and toxicology; infectious disease, including autoimmune; neurology diagnostics, including Alzheimer's disease; and women's health, such as prenatal genetic; workplace drug testing, testing urine, hair, and oral fluid specimens services; and employer population health services, including biometric screenings, flu shots, and related preventative services. Further, it provides population health solutions; extended care services; develops in vitro diagnostic tests; laboratory diagnostic information and digital health connectivity systems; underwriting support services, including data gathering, paramedical examinations, and clinical laboratory testing and analytics; and national specimen collection and health data solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

www.questdiagnostics.com

60,000

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 11/9/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

DGX
52.16%
S&P 500 (^GSPC)
10.29%

1-Year Return

DGX
47.10%
S&P 500 (^GSPC)
12.20%

3-Year Return

DGX
108.76%
S&P 500 (^GSPC)
73.67%

5-Year Return

DGX
101.36%
S&P 500 (^GSPC)
61.14%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 3.1B
Earnings 312M
Profit Margin 10.07%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

0
1B
2B
3B
9.0%
9.5%
10.0%
10.5%

Analyst Insights

View More

Analyst Price Targets

235.00 Low
257.27 Average
259.67 Current
279.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/7/2026
Analyst Barclays
Rating Action Maintains
Rating Overweight
Price Action Raises
Price Target 250 -> 260

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    9.53%

  • Return on Assets (ttm)

    6.61%

  • Return on Equity (ttm)

    15.32%

  • Revenue (ttm)

    11.84B

  • Net Income Avi to Common (ttm)

    1.12B

  • Diluted EPS (ttm)

    10.04

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    797M

  • Total Debt/Equity (mrq)

    79.65%

  • Levered Free Cash Flow (ttm)

    872.5M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: